Online inquiry

IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4817MR)

This product GTTS-WQ4817MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD4 gene. The antibody can be applied in Psoriasis, Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000616.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 920
UniProt ID P01730
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4817MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2575MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ10673MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ5221MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ2088MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ10398MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ12528MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ11081MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ3222MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARGX-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW